Your browser doesn't support javascript.
loading
Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins.
Torkildsen, Cecilie Fredvik; Austdal, Marie; Iversen, Ann-Charlotte; Bathen, Tone Frost; Giskeødegård, Guro Fanneløb; Nilsen, Elisabeth Berge; Iversen, Grete Alræk; Sande, Ragnar Kvie; Bjørge, Line; Thomsen, Liv Cecilie Vestrheim.
Afiliación
  • Torkildsen CF; Department of Obstetrics and Gynecology, Stavanger University Hospital, 4068 Stavanger, Norway.
  • Austdal M; Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.
  • Iversen AC; Department of Research, Stavanger University Hospital, 4068 Stavanger, Norway.
  • Bathen TF; Centre of Molecular Inflammation Research (CEMIR), Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway.
  • Giskeødegård GF; Department of Gynecology and Obstetrics, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway.
  • Nilsen EB; Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
  • Iversen GA; K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway.
  • Sande RK; Department of Obstetrics and Gynecology, Stavanger University Hospital, 4068 Stavanger, Norway.
  • Bjørge L; Department of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, Norway.
  • Thomsen LCV; Department of Obstetrics and Gynecology, Stavanger University Hospital, 4068 Stavanger, Norway.
Metabolites ; 13(3)2023 Mar 12.
Article en En | MEDLINE | ID: mdl-36984856
High-grade serous ovarian carcinoma (HGSOC) is the most common and deadliest ovarian cancer subtype. Despite advances in treatment, the overall prognosis remains poor. Regardless of efforts to develop biomarkers to predict surgical outcome and recurrence risk and resistance, reproducible indicators are scarce. Exploring the complex tumor heterogeneity, serum profiling of metabolites and lipoprotein subfractions that reflect both systemic and local biological processes were utilized. Furthermore, the overall impact on the patient from the tumor and the treatment was investigated. The aim was to characterize the systemic metabolic effects of primary treatment in patients with advanced HGSOC. In total 28 metabolites and 112 lipoproteins were analyzed by nuclear magnetic resonance (NMR) spectroscopy in longitudinal serum samples (n = 112) from patients with advanced HGSOC (n = 24) from the IMPACT trial with linear mixed effect models and repeated measures ANOVA simultaneous component analysis. The serum profiling revealed treatment-induced changes in both lipoprotein subfractions and circulating metabolites. The development of a more atherogenic lipid profile throughout the treatment, which was more evident in patients with short time to recurrence, indicates an enhanced systemic inflammation and increased risk of cardiovascular disease after treatment. The findings suggest that treatment-induced changes in the metabolome reflect mechanisms behind the diversity in disease-related outcomes.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Metabolites Año: 2023 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Metabolites Año: 2023 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Suiza